I Ischenko

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. ncbi Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice
    Daniela Bruell
    Department of Molecular Biotechnology, University Aachen, D 52074 Aachen, Germany
    Int J Mol Med 15:305-13. 2005
  2. ncbi Cancer stem cells: how can we target them?
    Ivan Ischenko
    Department of Surgery Grosshadern Campus, Medical Center of the University of Munich, Marchioninistr 15, D 81377 Munich, Germany
    Curr Med Chem 15:3171-84. 2008
  3. doi Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling
    I Ischenko
    Department of Surgery, Munich University Grosshadern Campus, Munich, Germany
    Oncogene 27:7212-22. 2008
  4. ncbi Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer
    Ivan Ischenko
    Department of Surgery, University of Munich Grosshadern LMU, Marchioninistr 15, Munich, Bavaria, 81377, Germany
    Angiogenesis 10:167-82. 2007
  5. ncbi Src tyrosine kinase inhibition suppresses lymphangiogenesis in vitro and in vivo
    I Ischenko
    Department of Surgery, Munich University Medical Center, Munich, Germany
    Curr Cancer Drug Targets 10:546-53. 2010
  6. doi Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications
    Ivan Ischenko
    Department of Surgery, Grosshadern Campus, Medical Center of the University of Munich, Marchioninistr 15, Munich, 81377, Germany
    Langenbecks Arch Surg 395:1-10. 2010
  7. ncbi The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1
    Gerald Schmid
    Department of Surgery, Ludwig Maximilian University, Klinikum Grosshadern, Munich, Germany
    J Cell Biochem 101:259-70. 2007
  8. ncbi Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model
    Claudius Conrad
    Department of Surgery, University of Munich Grosshadern LMU, Munich, Germany
    Anticancer Drugs 18:569-79. 2007
  9. doi The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis
    Andrea S Rothmeier
    Department of Pharmacy, Center for Drug Research, University of Munich, Munich, Germany
    Int J Cancer 127:1096-105. 2010
  10. ncbi FTY720 inhibits tumor growth and angiogenesis
    G Schmid
    Department of Surgery, University of Munich, Klinikum Grosshadern, Munich, Germany
    Transplant Proc 37:110-1. 2005

Collaborators

Detail Information

Publications18

  1. ncbi Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice
    Daniela Bruell
    Department of Molecular Biotechnology, University Aachen, D 52074 Aachen, Germany
    Int J Mol Med 15:305-13. 2005
    ..Our data suggest that EGFR-specific antibody toxins could be suitable for further clinical investigation in the development of therapies for pancreatic carcinoma...
  2. ncbi Cancer stem cells: how can we target them?
    Ivan Ischenko
    Department of Surgery Grosshadern Campus, Medical Center of the University of Munich, Marchioninistr 15, D 81377 Munich, Germany
    Curr Med Chem 15:3171-84. 2008
    ..This review provides a summary of some developments in the field of cancer stem cell targeting and highlights aspects where it could be of help in the drug discovery process...
  3. doi Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling
    I Ischenko
    Department of Surgery, Munich University Grosshadern Campus, Munich, Germany
    Oncogene 27:7212-22. 2008
    ..A potential mechanism of action of Src kinase inhibitors on 5-FU chemosensitivity might be linked to the inhibition of 5-FU-induced EGFR-AKT activation...
  4. ncbi Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer
    Ivan Ischenko
    Department of Surgery, University of Munich Grosshadern LMU, Marchioninistr 15, Munich, Bavaria, 81377, Germany
    Angiogenesis 10:167-82. 2007
    ..Taken together, our results suggest that the Src kinase inhibitor AZM475271, in addition to its effects on tumor cells, suppresses tumor growth and metastasis in vitro and in vivo potentially also by anti-angiogenic mechanisms...
  5. ncbi Src tyrosine kinase inhibition suppresses lymphangiogenesis in vitro and in vivo
    I Ischenko
    Department of Surgery, Munich University Medical Center, Munich, Germany
    Curr Cancer Drug Targets 10:546-53. 2010
    ..Here, we hypothesize that inhibition of the Src tyrosine kinase, apart from anti-hemangiogenic effects, results in a suppression of lymphangiogenesis...
  6. doi Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications
    Ivan Ischenko
    Department of Surgery, Grosshadern Campus, Medical Center of the University of Munich, Marchioninistr 15, Munich, 81377, Germany
    Langenbecks Arch Surg 395:1-10. 2010
    ..Among the most important properties of cancer stem cells their high capacity for tumorigenicity as well as their ability to metastasize is under special research interest today...
  7. ncbi The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1
    Gerald Schmid
    Department of Surgery, Ludwig Maximilian University, Klinikum Grosshadern, Munich, Germany
    J Cell Biochem 101:259-70. 2007
    ..Thus, in organ transplant patients, FTY720 may prove efficacious in preventing graft rejection as well as tumor development...
  8. ncbi Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model
    Claudius Conrad
    Department of Surgery, University of Munich Grosshadern LMU, Munich, Germany
    Anticancer Drugs 18:569-79. 2007
    ..ZD6474 decreased primary pancreatic tumor growth and reduced lymph node and liver metastases compared with controls or gemcitabine alone. Tumor growth was inhibited further in animals receiving ZD6474 and gemcitabine in combination...
  9. doi The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis
    Andrea S Rothmeier
    Department of Pharmacy, Center for Drug Research, University of Munich, Munich, Germany
    Int J Cancer 127:1096-105. 2010
    ....
  10. ncbi FTY720 inhibits tumor growth and angiogenesis
    G Schmid
    Department of Surgery, University of Munich, Klinikum Grosshadern, Munich, Germany
    Transplant Proc 37:110-1. 2005
    ..Therefore, a combination of FTY720 with an mTOR inhibitor might be the most favorable immunosuppressive drug combination for allograft recipients at risk for tumor development...
  11. doi Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine
    Axel Kleespies
    Department of Surgery, Klinikum Grosshadern, Ludwig Maximilian University, Munich, Germany
    Clin Cancer Res 14:5426-36. 2008
    ..We wanted to evaluate matuzumab (EMD72000), a fully humanized ErbB-1-specific monoclonal antibody in combination with gemcitabine in experimental pancreatic cancer...
  12. doi Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer
    Martin E Eichhorn
    Department of Surgery, Klinikum Grosshadern, University of Munich, Munich, Germany
    Int J Cancer 126:1235-45. 2010
    ..Therefore, this combination represents a promising novel strategy for clinical cancer therapy...
  13. doi EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma
    Hendrik Seeliger
    Munich University Medical Center, Department of Surgery, Munich, Germany
    Mol Cancer Res 7:189-98. 2009
    ..Hence, EFEMP1 is a promising candidate for assessing prognosis and individualizing therapy in a clinical tumor setting...
  14. doi Risk factors for surgical complications in distal pancreatectomy
    Hendrik Seeliger
    Department of Surgery, Munich University Medical Center, Germany
    Am J Surg 200:311-7. 2010
    ..Pancreatic fistula (PF) represents a major complication after distal pancreatectomy. In a consecutive series of 110 patients, risk factors for the incidence of PF and surgical morbidity were identified...
  15. ncbi Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF
    Markus Guba
    Department of Surgery, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
    Blood 105:4463-9. 2005
    ..Taken together, these data suggest that rapamycin, besides its known antiangiogenic properties, has a strong tumor-specific, antivascular effect in tumors...
  16. doi Investigation of the marine compound spongistatin 1 links the inhibition of PKCalpha translocation to nonmitotic effects of tubulin antagonism in angiogenesis
    Andrea S Rothmeier
    Department of Pharmacy, Center for Drug Research, University of Munich, Munich, Germany
    FASEB J 23:1127-37. 2009
    ..In addition, the data from the kinase array suggest that different tubulin antagonists might have individual intracellular actions...
  17. doi EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells
    Peter Camaj
    Department of Surgery, Munich University Medical Center, Campus Grosshadern, Marchioninistr 15, D 81377 Munich, Germany
    Biol Chem 390:1293-302. 2009
    ..The observed signal transduction upon treatment with EFEMP1 can contribute to the enhancement of tumor growth shown in pancreatic carcinoma cells overexpressing EFEMP1...
  18. doi Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma
    Christoph Zischek
    Clinical Biochemistry Group, Medical Policlinic, University of Munich, Munich, Germany
    Ann Surg 250:747-53. 2009
    ..To analyze the efficacy of engineered mesenchymal stem cell based therapy directed towards pancreatic tumor stroma...